BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 30659126)

  • 1. Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
    Leng S; Chen Y; Tsai WY; Bhutani D; Hillyer GC; Lim E; Accordino MK; Wright JD; Hershman DL; Lentzsch S; Neugut AI
    J Natl Compr Canc Netw; 2019 Jan; 17(1):22-28. PubMed ID: 30659126
    [No Abstract]   [Full Text] [Related]  

  • 2. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
    Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
    Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
    Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
    Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
    J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options in the management of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
    Sanfilippo KM; Gage B; Luo S; Weilbaecher K; Tomasson M; Vij R; Colditz G; Carson K
    Leuk Lymphoma; 2015 Mar; 56(3):615-21. PubMed ID: 24844358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
    Henk HJ; Teitelbaum A; Perez JR; Kaura S
    Am J Hematol; 2012 May; 87(5):490-5. PubMed ID: 22454220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
    Olszewski AJ; Barth PM; Reagan JL
    Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.
    Mateos MV; Fink L; Koneswaran N; Intorcia M; Giannopoulou C; Niepel D; Cavo M
    BMC Cancer; 2020 Mar; 20(1):170. PubMed ID: 32126974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study.
    Lee JY; Lee JH; Seo J; Kang M; Jung EH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    J Korean Med Sci; 2024 Jun; 39(22):e175. PubMed ID: 38859738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Mitsiades CS; Rosenblatt J; Mahindra A; Raje N; Munshi N; Anderson KC
    Eur J Haematol; 2012 Jan; 88(1):1-7. PubMed ID: 21991938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
    Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
    Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.